SK Biopharmaceuticals Co., Ltd. (KRX:326030)

SK Biopharmaceuticals Ratios and Metrics

Market cap in millions KRW. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 18, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	10,094,578	8,700,602	7,862,650	5,646,385	7,612,048	13,234,939
Market Cap Growth	32.07%	10.66%	39.25%	-25.82%	-42.48%	-
Enterprise Value	9,904,443	8,637,734	7,807,605	5,442,304	7,267,516	12,840,764
Last Close Price	128900.00	111100.00	100400.00	72100.00	97200.00	169000.00
PE Ratio	31.50	36.14	-	-	117.39	-
Forward PE	40.68	73.81	-	-	-	-
PS Ratio	14.95	15.89	22.16	22.94	18.18	509.06
PB Ratio	14.64	15.16	24.50	17.84	17.14	34.92
P/TBV Ratio	15.18	16.24	29.59	18.86	17.90	36.83
P/FCF Ratio	70.57	93.05	-	-	-	-
P/OCF Ratio	69.05	91.68	-	-	-	-
EV/Sales Ratio	14.66	15.77	22.00	22.11	17.36	493.89
EV/EBITDA Ratio	56.43	75.93	-	-	68.18	-
EV/EBIT Ratio	62.66	89.66	-	-	76.53	-
EV/FCF Ratio	69.24	92.38	-	-	-	-
Debt / Equity Ratio	0.07	0.32	0.56	0.49	0.04	0.05
Debt / EBITDA Ratio	0.23	1.62	-	-	0.15	-
Debt / FCF Ratio	0.35	1.97	-	-	-	-
Asset Turnover	0.75	0.62	0.51	0.38	0.73	0.08
Inventory Turnover	0.31	0.40	0.35	0.53	0.60	0.13
Quick Ratio	1.84	1.26	1.47	2.28	2.64	5.67
Current Ratio	2.43	1.64	2.02	2.99	3.18	6.16
Return on Equity (ROE)	58.15%	50.72%	-11.10%	-36.66%	15.75%	-135.18%
Return on Assets (ROA)	13.73%	6.84%	-3.38%	-12.53%	10.38%	-46.83%
Return on Capital (ROIC)	19.35%	9.58%	-4.83%	-17.57%	13.84%	-60.65%
Return on Capital Employed (ROCE)	25.90%	15.00%	-7.80%	-26.20%	19.20%	-55.70%
Earnings Yield	3.17%	2.77%	-0.42%	-2.47%	0.85%	-1.87%
FCF Yield	1.42%	1.07%	-1.23%	-2.92%	-1.28%	-1.68%
Buyback Yield / Dilution	-	-	-	-	-9.12%	-10.41%

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.